Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY Phase 2 imaging sub-study

Tuesday, January 2, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the positive results of Seralutinib in improving pulmonary arterial blood vessel volume distribution in patients with pulmonary arterial hypertension (PAH). These findings are based on the TORREY Phase 2 imaging sub-study, which highlights the potential therapeutic benefits of Seralutinib for PAH patients. The results may pave the way for further research and development in this area.
Price reaction · baseline $0.9125 (2023-12-29 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
+6.3%
day 1 · peak
+9.5%
day 3
-6.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows improvement in pulmonary arterial blood vessel volume distribution.
  • Results from the TORREY Phase 2 imaging sub-study indicate potential benefits for PAH patients.
  • The study contributes to the understanding of treatment effects in pulmonary arterial hypertension.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): Results of the TORREY Phase 2 imaging sub-study
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is Seralutinib used for?

Seralutinib is used to improve pulmonary arterial blood vessel volume distribution in PAH.

What were the results of the TORREY Phase 2 study?

The TORREY Phase 2 study showed that Seralutinib positively affects blood vessel volume distribution in PAH patients.

What condition does Seralutinib target?

Seralutinib targets pulmonary arterial hypertension (PAH).

What type of study was conducted for Seralutinib?

The study conducted was a Phase 2 imaging sub-study.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary arterial hypertension TORREY Phase 2 blood vessel volume
Last updated: Jan 2, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →